Trial Profile
Safety and Efficacy of Combination Biotherapy With High-Dose Interferon Alfa-2b and Anti-CTLA4 Monoclonal Antibody for Recurrent Inoperable Stage III or Stage IV Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Interferon alpha-2b (Primary) ; Tremelimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 28 Jan 2015 Planned End Date changed from 1 Jun 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 28 Jan 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.